Date

Fév 16 2021
Expiré!

Heure

1:00 pm - 5:30 pm

Theralymph First General Annual Meeting

Due to the restrictive and preventive measures put into place by the European countries, we met on February 16th 2021 by videoconference.

We were honored to introduce our consortium: Dr Kari Alitalo (Finland), Dr Tatiana Petrova (Switzerland), Dr Miikka Vikkula (Belgium), Dr Agnès Noël (Belgium), Dr Lenka Romeislova (Czeck Republic), Dr Gilles Pagès (France), Dr Taija Makinen (Sweden), Flash Therapeutics (France), the Clinical Investigation Center of Toulouse (France) and Inserm Tranfert.

Introduction : Lymphedema is a disorder of the lymphatic vascular system characterized by impaired lymphatic return and swelling of the extremities and accumulation of undrained interstitial fluid/lymph that results in fibrosis and adipose tissue deposition in the affected area. It can be an inherited condition (primary lymphedema) or occurs after cancer surgery and lymph node removal (secondary lymphedema). It causes a significant morbidity and is a common disabling disease affecting more than 120 million people worldwide, however there is no curative treatment for lymphedema. Therefore, our main objective will be to establish a multiple gene therapy for lymphedema. We will focus on women who developed secondary lymphedema after breast cancer. This meeting will consist in presenting the work teams as well as the distribution of each work packages in Theralymph project.

Programme horaire

Theralymph First General Annual Meeting

13:00 -
Welcome and overview of the meeting
Barbara Garmy-Susini
13:00 - 13:15
WP Objectives, achievements first 12 months and plans for the next 6 months
Christiane Dascher-Nadel (IT, Marseille France)
13:15 - 13:20
WP Objectives, achievements first 12 months and plans for the next 6 months
Barbara Garmy Susini, Inserm
13:20 - 13:40
WP1 Pathophysiology of lymphedema: risk factor associated with lymphedema - PARTNER PRESENTATIONS
Gilles Pages laboratory (CNRS) Barbara Garmy Susini laboratory (Inserm)
13:40 - 13:50
Discussion
13:50 - 14:20
WP2 Architecture of the collecting vessels in the adipose tissue - PARTNER PRESENTATIONS
Taija Mâkinen laboratory (UU) Barbara Garmy Susini laboratory (Inserm) Kari Alitalo (UnivHel) Miika Vikkula (DDUV)
14:20 - 14:35
Discussion
14:35 - 14:55
WP3 Adipocyte dysfunction in lymphedema - PARTNER PRESENTATIONS
Barbara Garmy Susini (Inserm) Lenka Rossmeislova (CUNI)
14:55 - 15:05
Discussion
15:05 - 15:25
WP4 Resolution of inflammation in lymphedema - PARTNER PRESENTATIONS
Tatiana Petrova (UNIL) Barbara Garmy Susini (Inserm)
15:25 - 15:35
Discussion
15:35 - 16:45
COFFEE BREAK
15:45 - 16:15
WP5 Validation of therapeutic targets in vitro - PARTNER PRESENTATIONS
Agnes Noël (ULIEGE) Barbara Garmy Susini (Inserm) Kari Alitalo (UnivHel) Tatiana Petrova (UNIL)
16:15 - 16:30
Discussion
16:30 - 17:00
WP6 Validation of therapeutic targets in vivo in mice model of lymhedema - PARTNER PRESENTATIONS
Barbara Garmy Susini (Inserm) Regis Gayon (FTX) Kari Alitalo (UnivHel) Agnes Noël (ULIEGE)
17:00 - 17:15
Discussion
17:15 - 17:30
GENERAL CONCLUSION
17:30 -
End of Meeting